Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The investigators are to evaluate the efficacy and safety of FOLFOX or FOLFIRI.3 combination
chemotherapy as second-line salvage chemotherapy in patients with advanced pancreatic
carcinoma.